The NAD+ IV vs oral NAD supplement question is not just about convenience. The two delivery routes produce meaningfully different pharmacokinetics, different clinical use cases, and different appropriate contexts. Understanding the difference matters for anyone considering NAD+ as part of a serious protocol.
Why NAD+ Isn't Directly Bioavailable Orally
NAD+ itself is a large, charged molecule that does not efficiently cross the intestinal epithelium or the cellular membrane in intact form. Oral supplementation of NAD+ itself is inefficient. This is why the oral supplement market has moved toward NAD+ precursors: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are more efficiently absorbed and then converted intracellularly to NAD+. These precursors do raise cellular NAD+ levels measurably, particularly with sustained dosing (Trammell et al., 2016; Yoshino et al., 2021).
How IV NAD+ Bypasses the Absorption Problem
IV NAD+ delivers the intact molecule directly into circulation, bypassing intestinal metabolism entirely. This produces meaningfully higher plasma NAD+ concentrations than any oral precursor protocol can achieve in the acute window. The clinical implication is that IV NAD+ is the appropriate tool when the therapeutic goal requires rapid, high-magnitude NAD+ elevation — most notably in acute detoxification, post-acute-withdrawal syndrome, and severe neurological or cognitive symptoms.
When Each Delivery Route Is Clinically Appropriate
IV NAD+ is our standard tool for acute-phase work at Sanctuary Tulum: opioid detox, benzodiazepine tapering, alcohol recovery, and post-acute neurological repair. Oral NR or NMN is generally more appropriate as a maintenance protocol — the daily supplementation model for longevity, mitochondrial support, and metabolic health in guests who are not in an acute clinical picture. The two are not competitive; they answer different questions.
The Cost, Access, and Setting Question
IV NAD+ requires a clinical setting, trained staff, and multi-hour infusion sessions, which is why the treatment is typically delivered in residential or specialist infusion contexts rather than at home. Oral precursors are shelf-available and self-administered. Cost per protocol favors oral; clinical magnitude of effect in acute settings favors IV. Neither is universally superior — the correct choice is determined by the clinical goal. See our NAD+ rapid detox protocol.
What the Trial Evidence Actually Supports
IV NAD+ has a smaller RCT base than oral precursors but a longer clinical use history in addiction medicine, with observational and case-series data supporting its role in reducing acute withdrawal severity and post-acute cognitive symptoms. Oral NR and NMN have more rigorous pharmacokinetic and safety data but a still-emerging clinical outcome literature. Both are reasonable interventions in appropriate contexts; neither is a standalone cure. Explore our full NAD+ IV therapy program.
